Today, the pharmaceutical industry has a net outflow of 2 billion yuan, with Hanyu Pharmaceutical, Meinian Health and Huahai Pharmaceutical in the lead

The Shanghai index rose 0.
05% on January 12, and 13 of Shenwan's industries rose today
.
The pharmaceutical and biotechnology sector fell 0.
41%
today.
From the perspective of funds, the main funds of the two cities had a net outflow of 11.
796 billion yuan throughout the day, and there were 26 industries with a net outflow of main funds
.
Among them, the net outflow of the main funds of the pharmaceutical and biological industry ranked first, with a net outflow of 2 billion yuan
throughout the day.
According to the statistics of capital flow data, among the net outflow of funds from the pharmaceutical and biological industry, there are 8 stocks with a net outflow of more than 50 million yuan, namely Hanyu Pharmaceutical, Meinian Health, Huahai Pharmaceutical, Fosun Pharma, Watson Biotechnology, Xingqi Eye Medicine, Nuotai Biotechnology, and Shanghai RAAS
.
Among them, Hanyu Pharmaceutical's net outflow of 162 million yuan ranked first
.
Data show that on January 12, Hanyu Pharmaceutical fell by 5% intraday, and as of 13:14, it was reported at 17.
2 yuan, with a transaction of 502 million yuan and a turnover rate of 4.
06%.

According to the data, Hanyu Pharmaceutical's business covers the field of drugs and medical devices, and its main products include six series of products: peptide preparations, peptide APIs, customer peptides, solid dosages, drug combination packaging and medical devices
.
On January 12, Hanyu Pharmaceutical said on the investor interactive platform that the company's immunomodulators have thymus faxin for injection, thymus pentapeptide for injection, and thymus peptide injection is not the same drug, the company's thymus faxin for injection and thymus pentapeptide for injection are important active components in human thymus hormone, which are synthesized artificially, have high safety, and adverse reactions are usually mild and uncommon
.
The company's thymus faxin has passed the consistency evaluation of the quality and efficacy of generic drugs, and the product quality is stable and reliable
.
Thymus peptide injection is extracted from the thymus gland of animals, which carries the risk
of allergies.
In addition, Hanyu Pharmaceutical also said in the interactive platform that the company's HY3000 nasal spray was selected as the fourth batch of key projects
of the Guangdong Provincial Food and Drug Administration.
The company's vildagliptin tablets for the treatment of diabetes recently received the "Drug Registration Certificate" issued by the State Food and Drug Administration and is deemed to have passed the consistency evaluation
.
The net outflow of Meinian Health was 123 million yuan
.
Data show that on January 12, Meinian Health fell by 5% intraday, and as of 11:22, it was 6.
06 yuan, with a transaction of 464 million yuan and a turnover rate of 1.
92%.

Analysts pointed out that with the increase in the number of demand for lung CT examination in various places, many physical examination institutions have rushed to launch "Yangkang" physical examination packages, and the health examination track has once again attracted market attention
.
Meinian Health, a listed company, recently said that the newly launched "Yangkang" safety inspection standard model has currently sold 155815 pieces, with a single piece of 529 yuan and a turnover of 82.
42 million.

Meinian health staff said that the development trend of health examination and preventive medicine industry will change from simple business to discipline construction, from simple physical examination to health management, from simple disease examination to the integration of screening, diagnosis and treatment, and the core capabilities of the transformation come from the mastery and application
of digitalization, intelligence and standardization.
Huahai Pharmaceutical's net outflow was RMB107 million
.
On January 12, Huahai Pharmaceutical fell 7%, and data from the Dragon and Tiger List showed that the sales department seats on the list traded 370 million yuan throughout the day, accounting for 21.
51%
of the total transaction amount on the day.
According to the data, Huahai Pharmaceutical is a listed pharmaceutical enterprise
integrating chemical drugs, biological drugs, pharmaceutical packaging and trade circulation.
The company has formed a series of products
led by cardiovascular, mental disorders, nervous system and anti-infection.
It is reported that on January 11, Huahai Pharmaceutical issued an announcement that the company recently received the "Drug Registration Certificate"
of felodipine sustained-release tablets approved and issued by the State Medical Products Administration.
The drug is mainly used in the treatment
of hypertension and stable angina.
In addition to the above three enterprises, on January 12, Fosun Pharma, Watson Biotechnology, Xingqi Eye Medicine, Nuotai Biotech and Shanghai RAAS had a net outflow of 73.
2623 million yuan, 72.
2918 million yuan, 64.
8466 million yuan, 59.
7066 million yuan and 54.
7713 million yuan respectively
.
The data also shows that on January 12, there were 149 stocks with a net inflow of funds in the pharmaceutical and biological industry, of which 6 had a net inflow of more than 30 million yuan, namely WuXi AppTec, Yingke Medical, Junshi Biologics, Zhongsheng Pharmaceutical, Pian Zixi and Yiling Pharmaceutical
.
WuXi AppTec had the highest net inflow of funds, with a net inflow of 119 million yuan today, followed by Inco Medical and Junshi Biologics, with net inflows of 78.
0016 million yuan and 74.
3091 million
yuan respectively.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.